RKDA (Arcadia Biosciences) Cyclically Adjusted Revenue per Share: $27.25 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RKDA Arcadia Biosciences Inc RKDA
43 GF Score
Price $0.56
GF Value $2.84
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Arcadia Biosciences Cyclically Adjusted Revenue per Share?

Arcadia Biosciences RKDA -18.59% 43 Cyclically Adjusted Revenue per Share is $27.25 as of Mar. 2026. GuruFocus rates RKDA with a GF Score™ of 43/100 and a GF Value™ of $2.84 (Possible Value Trap). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Arcadia Biosciences's adjusted revenue per share for the three months ended in Mar. 2026 was $0.528. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $27.25 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Arcadia Biosciences's average Cyclically Adjusted Revenue Growth Rate was -35.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-13), Arcadia Biosciences's current stock price is $0.56. Arcadia Biosciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $27.25. Arcadia Biosciences's Cyclically Adjusted PS Ratio of today is 0.02.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Arcadia Biosciences was 0.17. The lowest was 0.02. And the median was 0.05.


Arcadia Biosciences  (NAS:RKDA) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Arcadia Biosciences's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.56/27.25
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Arcadia Biosciences was 0.17. The lowest was 0.02. And the median was 0.05.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Arcadia Biosciences Cyclically Adjusted Revenue per Share Related Terms


Arcadia Biosciences Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Arcadia Biosciences's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arcadia Biosciences Cyclically Adjusted Revenue per Share Chart

Arcadia Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 64.43 43.93 28.79

Arcadia Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.30 36.33 32.16 28.79 27.25

RKDA vs ORISF, ARRT, CIMG: Cyclically Adjusted Revenue per Share Comparison

For the Packaged Foods subindustry, Arcadia Biosciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arcadia Biosciences Cyclically Adjusted PS Ratio vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Arcadia Biosciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Arcadia Biosciences's Cyclically Adjusted PS Ratio falls into.


RKDA
43GF Score
Arcadia Biosciences Inc RKDA
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arcadia Biosciences Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Arcadia Biosciences's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.528/330.2130*330.2130
=0.528

Current CPI (Mar. 2026) = 330.2130.

Arcadia Biosciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 13.109 241.018 17.960
201609 19.545 241.428 26.733
201612 9.643 241.432 13.189
201703 18.509 243.801 25.069
201706 18.698 244.955 25.206
201709 11.113 246.819 14.868
201712 26.943 246.524 36.090
201803 3.891 249.554 5.149
201806 5.253 251.989 6.884
201809 3.109 252.439 4.067
201812 3.700 251.233 4.863
201903 1.328 254.202 1.725
201906 1.611 256.143 2.077
201909 2.253 256.759 2.898
201912 1.917 256.974 2.463
202003 1.424 258.115 1.822
202006 1.206 257.797 1.545
202009 1.172 260.280 1.487
202012 25.647 260.474 32.514
202103 1.739 264.877 2.168
202106 2.583 271.696 3.139
202109 4.289 274.310 5.163
202112 3.912 278.802 4.633
202203 5.802 287.504 6.664
202206 6.951 296.311 7.746
202209 2.557 296.808 2.845
202212 1.104 296.797 1.228
202303 1.426 301.836 1.560
202306 0.955 305.109 1.034
202309 0.954 307.789 1.024
202312 0.570 306.746 0.614
202403 0.725 312.332 0.767
202406 0.958 314.175 1.007
202409 1.127 315.301 1.180
202412 0.891 315.605 0.932
202503 0.878 319.799 0.907
202506 1.064 322.561 1.089
202509 0.949 324.800 0.965
202512 0.657 324.054 0.669
202603 0.528 330.213 0.528

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $27.25 mean?
Arcadia Biosciences (RKDA) has a Cyclically Adjusted Revenue per Share of $27.25 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Arcadia Biosciences and its competitors.
Is Arcadia Biosciences' Cyclically Adjusted Revenue per Share too high?
Arcadia Biosciences' current Cyclically Adjusted Revenue per Share is $27.25. Overall, Arcadia Biosciences has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arcadia Biosciences' Cyclically Adjusted Revenue per Share compare to ORISF and ARRT?
Arcadia Biosciences' Cyclically Adjusted Revenue per Share of $27.25 can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Consumer Packaged Goods company?
A good Cyclically Adjusted Revenue per Share depends on the Consumer Packaged Goods industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Arcadia Biosciences and its competitors. Arcadia Biosciences's current Cyclically Adjusted Revenue per Share is $27.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcadia Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Arcadia Biosciences (RKDA) is currently considered Possible Value Trap. The stock's GF Value™ is $2.84, compared to a current price of $0.56 — trading 80.3% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $27.25. Arcadia Biosciences' overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Arcadia Biosciences (RKDA), the current Cyclically Adjusted Revenue per Share is $27.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arcadia Biosciences (RKDA) Overvalued in 2026?

Based on GuruFocus' analysis, Arcadia Biosciences stock appears to be undervalued. The current stock price of $0.56 is trading 80.3% below its estimated GF Value™ of $2.84. GuruFocus considers Arcadia Biosciences to be Possible Value Trap.

Key valuation signals for RKDA:

  • Cyclically Adjusted Revenue per Share: $27.25
  • GF Value™: $2.84 vs. price of $0.56 (80.3% below fair value)
  • GF Score™: 43/100 with 4 warning signs

No single metric tells the full story. See the RKDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Arcadia Biosciences Business Description

Address 5950 Sherry Lane, Suite 2000, Dallas, TX, USA, 75225
Arcadia Biosciences Inc is a company with science-based approaches to develop high value products and drive innovation in the consumer goods industry. The company has one operating and reportable segment, which derives revenue from the sale of Zola coconut water. The company's consumer brands in the food, beverage, and body care categories, and others. Its products include: Zola Coconut Water, and Agronomic Wheat Traits. Geographically, the company operates in United States, Argentina, India, and Canada. It derives maximum revenue from United States.
43GF Score

Get the complete analysis for RKDA

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.56
Price
$2.84
GF Value